This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CTI BioPharma Yönetim

Yönetim kriter kontrolleri 3/4

CTI BioPharma CEO'su Adam Craig, Mar2017 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 4.59M olup, şirket hissesi ve opsiyonları dahil olmak üzere 14.3% maaş ve 85.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.022% ine doğrudan sahiptir ve bu hisseler $ 267.56K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6 yıl ve 6.3 yıldır.

Anahtar bilgiler

Adam Craig

İcra Kurulu Başkanı

US$4.6m

Toplam tazminat

CEO maaş yüzdesi	14.3%
CEO görev süresi	6.3yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	6yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

Aug 17

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

Aug 08

CTI BioPharma: Approval Is Great, Now There's The Follow Through

Jul 19

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

Jul 07

CEO Tazminat Analizi

Adam Craig'un ücretlendirmesi CTI BioPharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$5m	US$657k	-US$93m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$121m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$2m	US$633k	-US$98m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$3m	US$615k	-US$52m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$44m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$2m	US$595k	-US$40m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$3m	US$564k	-US$29m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$42m
Mar 31 2018	n/a	n/a	-US$29m
Dec 31 2017	US$6m	US$434k	-US$45m

Tazminat ve Piyasa: Adam 'ın toplam tazminatı ($USD 4.59M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 3.15M ).

Tazminat ve Kazançlar: Adam şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Adam Craig (57 yo)

6.3yrs

Görev süresi

US$4,592,646

Tazminat

Dr. Adam R. Craig, M.D., Ph D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
David Kirske	Executive VP	5.8yrs	US$1.47m	0.013% $ 155.7k
James Fong	Executive VP & Chief Commercial Officer	no data	US$597.30k	0.0027% $ 32.4k
Ed Bell	Senior Director of Investor Relations	15yrs	Veri yok	Veri yok
Bruce Bennett	Senior Vice President Global Pharmaceutical Operations	no data	Veri yok	Veri yok
John Volpone	Executive VP & Chief of Staff	no data	Veri yok	Veri yok
Jennifer Smith	Senior Vice President of Biometrics	4.6yrs	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim: CTIC 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Craig	President	6.3yrs	US$4.59m	0.022% $ 267.6k
Diane Parks	Independent Director	1.8yrs	US$301.12k	0% $ 0
Daniel Von Hoff	Chairman of Scientific Advisory Board	9.9yrs	Veri yok	Veri yok
Laurent Fischer	Independent Chairman of the Board	5.9yrs	US$352.12k	0% $ 0
David Parkinson	Independent Director	6yrs	US$317.62k	0% $ 0
Matthew Perry	Independent Director	7.4yrs	US$303.62k	0.033% $ 392.1k
Reed Tuckson	Independent Director	11.8yrs	US$319.12k	0.037% $ 442.1k
Michael Metzger	Independent Director	6.4yrs	US$330.62k	0% $ 0

6.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CTIC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.3 yıldır).

This company listing is no longer active

CTI BioPharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

Recent updates

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) completed the acquisition of CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders.

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index

CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Value Index

Swedish Orphan Biovitrum AB (publ) (OM:SOBI) entered into a definitive agreement and plan of merger to acquire CTI BioPharma Corp. (NasdaqCM:CTIC) from a group of shareholders for $1.2 billion.

CTI BioPharma Corp. to Report Q3, 2022 Results on Nov 07, 2022

CTI BioPharma Corp. Announces Executive Changes

CTI BioPharma Corp. Announces Presentation of New Anemia Benefit Data from Pacritinib Program At the Society of Hematologic Oncology Tenth Annual Meeting

CTI BioPharma: Reiterating Target Price Of $17 After Successful VONJO Launch

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma GAAP EPS of -$0.21 misses by $0.01, revenue of $12.33M beats by $3.23M

CTI BioPharma Corp. to Report Q2, 2022 Results on Aug 08, 2022

CTI BioPharma: Approval Is Great, Now There's The Follow Through

CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

CTI BioPharma Corp., Annual General Meeting, Jun 01, 2022

National Comprehensive Cancer Network Recommends CTI BioPharma Corp.'s VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. appoints James K. Fong as senior vice president and chief commercial officer

CTI BioPharma Corp. Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

CTI BioPharma: A Speculative Buy Into The PDUFA Date

CTI BioPharma: Long And Troubled History, Finally Approaching Approval

CTI BioPharma Corp. Announces Extension of FDA Review Period for Pacritinib in Myelofibrosis with Severe Thrombocytopenia

CTI BioPharma Corp. Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

FDA grants 'priority review' status to CTI Biopharma's pacritinib NDA

CTI BioPharma initiated buy at Stifel; cites potential in myelofibrosis

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q4, 2020 Results on Mar 17, 2021

CTI BioPharma: Accelerated Approval Pathway Looks Attractive

Cti Biopharma Corp. Announces Publication of Article Highlighting Pacritinib Data from the Pac203 Phase 2 Study in Myelofibrosis in Blood Advances

CTI BioPharma Corp. Contemplates Bankruptcy

CTI BioPharma Corp. to Report Q3, 2020 Results on Nov 10, 2020

CTI BioPharma Corp. Initiates Rolling Submission of New Drug Application for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia

CTI BioPharma Corp. Contemplates Bankruptcy

Earnings released

New 90-day high - US$1.60

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş